Disruption of lamin B1 and lamin B2 processing and localization by farnesyltransferase inhibitors

References

• Gonzalez JM, Pla D, Perez-Sala D, Andres V. A-type lamins and Hutchinson-Gilford progeria syndrome: pathogenesis and therapy. [Schol Ed] Front Biosci (Schol Ed) 2011; 3:1133 - 46; http://dx.doi.org/10.2741/216; PMID: 21622261
   PubMedGoogle Scholar
• Reddy S, Comai L. Lamin A, farnesylation and aging. Exp Cell Res 2012; 318:1 - 7; http://dx.doi.org/10.1016/j.yexcr.2011.08.009; PMID: 21871450
   PubMed Web of Science ®Google Scholar
• Adam SA, Goldman RD. Insights into the differences between the Aand B-type nuclear lamins. Adv Biol Regul 2012; 52:108 - 13; http://dx.doi.org/10.1016/j.advenzreg.2011.11.001; PMID: 22119859
   PubMedGoogle Scholar
• Rusiñol AE, Sinensky MS. Farnesylated lamins, progeroid syndromes and farnesyl transferase inhibitors. J Cell Sci 2006; 119:3265 - 72; http://dx.doi.org/10.1242/jcs.03156; PMID: 16899817
   PubMed Web of Science ®Google Scholar
• De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, et al. Lamin a truncation in Hutchinson-Gilford progeria. Science 2003; 300:2055; http://dx.doi.org/10.1126/science.1084125; PMID: 12702809
   PubMed Web of Science ®Google Scholar
• Dechat T, Shimi T, Adam SA, Rusinol AE, Andres DA, Spielmann HP, et al. Alterations in mitosis and cell cycle progression caused by a mutant lamin A known to accelerate human aging. Proc Natl Acad Sci U S A 2007; 104:4955 - 60; http://dx.doi.org/10.1073/pnas.0700854104; PMID: 17360326
   PubMed Web of Science ®Google Scholar
• Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003; 423:293 - 8; http://dx.doi.org/10.1038/nature01629; PMID: 12714972
   PubMed Web of Science ®Google Scholar
• Glynn MW, Glover TW. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum Mol Genet 2005; 14:2959 - 69; http://dx.doi.org/10.1093/hmg/ddi326; PMID: 16126733
   PubMed Web of Science ®Google Scholar
• Toth JI, Yang SH, Qiao X, Beigneux AP, Gelb MH, Moulson CL, et al. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc Natl Acad Sci U S A 2005; 102:12873 - 8; http://dx.doi.org/10.1073/pnas.0505767102; PMID: 16129834
   PubMed Web of Science ®Google Scholar
• Mallampalli MP, Huyer G, Bendale P, Gelb MH, Michaelis S. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2005; 102:14416 - 21; http://dx.doi.org/10.1073/pnas.0503712102; PMID: 16186497
   PubMed Web of Science ®Google Scholar
• Yang SH, Bergo MO, Toth JI, Qiao X, Hu Y, Sandoval S, et al. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci U S A 2005; 102:10291 - 6; http://dx.doi.org/10.1073/pnas.0504641102; PMID: 16014412
   PubMed Web of Science ®Google Scholar
• Yang SH, Meta M, Qiao X, Frost D, Bauch J, Coffinier C, et al. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest 2006; 116:2115 - 21; http://dx.doi.org/10.1172/JCI28968; PMID: 16862216
   PubMed Web of Science ®Google Scholar
• Capell BC, Erdos MR, Madigan JP, Fiordalisi JJ, Varga R, Conneely KN, et al. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2005; 102:12879 - 84; http://dx.doi.org/10.1073/pnas.0506001102; PMID: 16129833
   PubMed Web of Science ®Google Scholar
• Capell BC, Olive M, Erdos MR, Cao K, Faddah DA, Tavarez UL, et al. A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc Natl Acad Sci U S A 2008; 105:15902 - 7; http://dx.doi.org/10.1073/pnas.0807840105; PMID: 18838683
   PubMed Web of Science ®Google Scholar
• Fong LG, Frost D, Meta M, Qiao X, Yang SH, Coffinier C, et al. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 2006; 311:1621 - 3; http://dx.doi.org/10.1126/science.1124875; PMID: 16484451
   PubMed Web of Science ®Google Scholar
• Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhard-Herman M, et al. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2012; 109:16666 - 71; http://dx.doi.org/10.1073/pnas.1202529109; PMID: 23012407
   PubMed Web of Science ®Google Scholar
• Dalton MB, Fantle KS, Bechtold HA, DeMaio L, Evans RM, Krystosek A, et al. The farnesyl protein transferase inhibitor BZA-5B blocks farnesylation of nuclear lamins and p21ras but does not affect their function or localization. Cancer Res 1995; 55:3295 - 304; PMID: 7614464
   PubMed Web of Science ®Google Scholar
• Mégnin-Chanet F, Lavelle F, Favaudon V. The farnesyl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distribution. BMC Pharmacol 2002; 2:2; http://dx.doi.org/10.1186/1471-2210-2-2; PMID: 11929613
   PubMedGoogle Scholar
• Kitten GT, Nigg EA. The CaaX motif is required for isoprenylation, carboxyl methylation, and nuclear membrane association of lamin B2. J Cell Biol 1991; 113:13 - 23; http://dx.doi.org/10.1083/jcb.113.1.13; PMID: 2007618
   PubMed Web of Science ®Google Scholar
• Verstraeten VL, Peckham LA, Olive M, Capell BC, Collins FS, Nabel EG, et al. Protein farnesylation inhibitors cause donut-shaped cell nuclei attributable to a centrosome separation defect. Proc Natl Acad Sci U S A 2011; 108:4997 - 5002; http://dx.doi.org/10.1073/pnas.1019532108; PMID: 21383178
   PubMed Web of Science ®Google Scholar
• Shimi T, Pfleghaar K, Kojima S, Pack CG, Solovei I, Goldman AE, et al. The A- and B-type nuclear lamin networks: microdomains involved in chromatin organization and transcription. Genes Dev 2008; 22:3409 - 21; http://dx.doi.org/10.1101/gad.1735208; PMID: 19141474
   PubMed Web of Science ®Google Scholar
• Burke B, Mounkes LC, Stewart CL. The nuclear envelope in muscular dystrophy and cardiovascular diseases. Traffic 2001; 2:675 - 83; http://dx.doi.org/10.1034/j.1600-0854.2001.21001.x; PMID: 11576443
   PubMed Web of Science ®Google Scholar
• Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, Gordon LB, et al. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2004; 101:8963 - 8; http://dx.doi.org/10.1073/pnas.0402943101; PMID: 15184648
   PubMed Web of Science ®Google Scholar
• Taimen P, Pfleghaar K, Shimi T, Möller D, Ben-Harush K, Erdos MR, et al. A progeria mutation reveals functions for lamin A in nuclear assembly, architecture, and chromosome organization. Proc Natl Acad Sci U S A 2009; 106:20788 - 93; http://dx.doi.org/10.1073/pnas.0911895106; PMID: 19926845
   PubMed Web of Science ®Google Scholar
• Coffinier C, Chang SY, Nobumori C, Tu Y, Farber EA, Toth JI, et al. Abnormal development of the cerebral cortex and cerebellum in the setting of lamin B2 deficiency. Proc Natl Acad Sci U S A 2010; 107:5076 - 81; http://dx.doi.org/10.1073/pnas.0908790107; PMID: 20145110
   PubMed Web of Science ®Google Scholar
• Coffinier C, Jung HJ, Nobumori C, Chang S, Tu Y, Barnes RH 2nd, et al. Deficiencies in lamin B1 and lamin B2 cause neurodevelopmental defects and distinct nuclear shape abnormalities in neurons. Mol Biol Cell 2011; 22:4683 - 93; http://dx.doi.org/10.1091/mbc.E11-06-0504; PMID: 21976703
   PubMed Web of Science ®Google Scholar
• Kim Y, Sharov AA, McDole K, Cheng M, Hao H, Fan CM, et al. Mouse B-type lamins are required for proper organogenesis but not by embryonic stem cells. Science 2011; 334:1706 - 10; http://dx.doi.org/10.1126/science.1211222; PMID: 22116031
   PubMed Web of Science ®Google Scholar
• Shimi T, Butin-Israeli V, Adam SA, Hamanaka RB, Goldman AE, Lucas CA, et al. The role of nuclear lamin B1 in cell proliferation and senescence. Genes Dev 2011; 25:2579 - 93; http://dx.doi.org/10.1101/gad.179515.111; PMID: 22155925
   PubMed Web of Science ®Google Scholar
• Young SG, Meta M, Yang SH, Fong LG. Prelamin A farnesylation and progeroid syndromes. J Biol Chem 2006; 281:39741 - 5; http://dx.doi.org/10.1074/jbc.R600033200; PMID: 17090536
   PubMed Web of Science ®Google Scholar
• Lehner CF, Fürstenberger G, Eppenberger HM, Nigg EA. Biogenesis of the nuclear lamina: in vivo synthesis and processing of nuclear protein precursors. Proc Natl Acad Sci U S A 1986; 83:2096 - 9; http://dx.doi.org/10.1073/pnas.83.7.2096; PMID: 3515346
   PubMed Web of Science ®Google Scholar
• Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, et al. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol 2007; 25:3137 - 43; http://dx.doi.org/10.1200/JCO.2006.09.4243; PMID: 17634493
   PubMed Web of Science ®Google Scholar
• Castaneda C, Meadows KL, Truax R, Morse MA, Kaufmann SH, Petros WP, et al. Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; 67:455 - 63; http://dx.doi.org/10.1007/s00280-010-1488-5; PMID: 20972873
   PubMed Web of Science ®Google Scholar
• Varela I, Pereira S, Ugalde AP, Navarro CL, Suárez MF, Cau P, et al. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med 2008; 14:767 - 72; http://dx.doi.org/10.1038/nm1786; PMID: 18587406
   PubMed Web of Science ®Google Scholar
• Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004; 30:609 - 41; http://dx.doi.org/10.1016/j.ctrv.2004.06.010; PMID: 15531395
   PubMed Web of Science ®Google Scholar
• Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000; 19:6584 - 93; http://dx.doi.org/10.1038/sj.onc.1204146; PMID: 11426643
   PubMed Web of Science ®Google Scholar
• Cristofalo VJ, Pignolo RJ. Replicative senescence of human fibroblast-like cells in culture. Physiol Rev 1993; 73:617 - 38; PMID: 8332640
   PubMed Web of Science ®Google Scholar
• Freund A, Laberge RM, Demaria M, Campisi J. Lamin B1 loss is a senescence-associated biomarker. Mol Biol Cell 2012; 23:2066 - 75; http://dx.doi.org/10.1091/mbc.E11-10-0884; PMID: 22496421
   PubMed Web of Science ®Google Scholar
• Lutz RJ, Trujillo MA, Denham KS, Wenger L, Sinensky M. Nucleoplasmic localization of prelamin A: implications for prenylation-dependent lamin A assembly into the nuclear lamina. Proc Natl Acad Sci U S A 1992; 89:3000 - 4; http://dx.doi.org/10.1073/pnas.89.7.3000; PMID: 1557405
   PubMed Web of Science ®Google Scholar
• Sinensky M, Fantle K, Trujillo M, McLain T, Kupfer A, Dalton M. The processing pathway of prelamin A. J Cell Sci 1994; 107:61 - 7; PMID: 8175923
   PubMed Web of Science ®Google Scholar
• Hennekes H, Nigg EA. The role of isoprenylation in membrane attachment of nuclear lamins. A single point mutation prevents proteolytic cleavage of the lamin A precursor and confers membrane binding properties. J Cell Sci 1994; 107:1019 - 29; PMID: 8056827
   PubMed Web of Science ®Google Scholar
• Krohne G, Waizenegger I, Höger TH. The conserved carboxy-terminal cysteine of nuclear lamins is essential for lamin association with the nuclear envelope. J Cell Biol 1989; 109:2003 - 11; http://dx.doi.org/10.1083/jcb.109.5.2003; PMID: 2808518
   PubMed Web of Science ®Google Scholar
• Lee R, Chang SY, Trinh H, Tu Y, White AC, Davies BS, et al. Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes. Hum Mol Genet 2010; 19:1603 - 17; http://dx.doi.org/10.1093/hmg/ddq036; PMID: 20106865
   PubMed Web of Science ®Google Scholar
• Davies BS, Barnes RH 2nd, Tu Y, Ren S, Andres DA, Spielmann HP, et al. An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria. Hum Mol Genet 2010; 19:2682 - 94; http://dx.doi.org/10.1093/hmg/ddq158; PMID: 20421363
   PubMed Web of Science ®Google Scholar
• Rahman-Roblick R, Roblick UJ, Hellman U, Conrotto P, Liu T, Becker S, et al. p53 targets identified by protein expression profiling. Proc Natl Acad Sci U S A 2007; 104:5401 - 6; http://dx.doi.org/10.1073/pnas.0700794104; PMID: 17372198
   PubMed Web of Science ®Google Scholar
• Gerace L, Huber MD. Nuclear lamina at the crossroads of the cytoplasm and nucleus. J Struct Biol 2012; 177:24 - 31; http://dx.doi.org/10.1016/j.jsb.2011.11.007; PMID: 22126840
   PubMed Web of Science ®Google Scholar
• Zhang YQ, Sarge KD. Sumoylation regulates lamin A function and is lost in lamin A mutants associated with familial cardiomyopathies. J Cell Biol 2008; 182:35 - 9; http://dx.doi.org/10.1083/jcb.200712124; PMID: 18606848
   PubMed Web of Science ®Google Scholar
• Gerace L, Blobel G. The nuclear envelope lamina is reversibly depolymerized during mitosis. Cell 1980; 19:277 - 87; http://dx.doi.org/10.1016/0092-8674(80)90409-2; PMID: 7357605
   PubMed Web of Science ®Google Scholar
• Adolph KW. ADPribosylation of nuclear proteins labeled with [3H]adenosine: changes during the HeLa cycle. Biochim Biophys Acta 1987; 909:222 - 30; http://dx.doi.org/10.1016/0167-4781(87)90081-9; PMID: 3040104
   PubMed Web of Science ®Google Scholar
• Moulson CL, Go G, Gardner JM, van der Wal AC, Smitt JH, van Hagen JM, et al. Homozygous and compound heterozygous mutations in ZMPSTE24 cause the laminopathy restrictive dermopathy. J Invest Dermatol 2005; 125:913 - 9; http://dx.doi.org/10.1111/j.0022-202X.2005.23846.x; PMID: 16297189
   PubMed Web of Science ®Google Scholar
• Yang SH, Andres DA, Spielmann HP, Young SG, Fong LG. Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated. J Clin Invest 2008; 118:3291 - 300; http://dx.doi.org/10.1172/JCI35876; PMID: 18769635
   PubMed Web of Science ®Google Scholar
• Yang SH, Chang SY, Ren S, Wang Y, Andres DA, Spielmann HP, et al. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin. Hum Mol Genet 2011; 20:436 - 44; http://dx.doi.org/10.1093/hmg/ddq490; PMID: 21088111
   PubMed Web of Science ®Google Scholar
• Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH. Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res 2000; 6:2318 - 25; PMID: 10873082
   PubMed Web of Science ®Google Scholar
• Tamanoi F, Kato-Stankiewicz J, Jiang C, Machado I, Thapar N. Farnesylated proteins and cell cycle progression. J Cell Biochem Suppl 2001; Suppl 37 64 - 70; http://dx.doi.org/10.1002/jcb.10067; PMID: 11842430
   PubMedGoogle Scholar
• Tsai MY, Wang S, Heidinger JM, Shumaker DK, Adam SA, Goldman RD, et al. A mitotic lamin B matrix induced by RanGTP required for spindle assembly. Science 2006; 311:1887 - 93; http://dx.doi.org/10.1126/science.1122771; PMID: 16543417
   PubMed Web of Science ®Google Scholar
• Yang SH, Chang SY, Tu Y, Lawson GW, Bergo MO, Fong LG, et al. Severe hepatocellular disease in mice lacking one or both CaaX prenyltransferases. J Lipid Res 2012; 53:77 - 86; http://dx.doi.org/10.1194/jlr.M021220; PMID: 22039581
   PubMed Web of Science ®Google Scholar
• Hegele RA, Cao H, Liu DM, Costain GA, Charlton-Menys V, Rodger NW, et al. Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy. Am J Hum Genet 2006; 79:383 - 9; http://dx.doi.org/10.1086/505885; PMID: 16826530
   PubMed Web of Science ®Google Scholar
• Yang SH, Chang SY, Yin L, Tu Y, Hu Y, Yoshinaga Y, et al. An absence of both lamin B1 and lamin B2 in keratinocytes has no effect on cell proliferation or the development of skin and hair. Hum Mol Genet 2011; 20:3537 - 44; http://dx.doi.org/10.1093/hmg/ddr266; PMID: 21659336
   PubMed Web of Science ®Google Scholar
• Yoon BC, Jung H, Dwivedy A, O’Hare CM, Zivraj KH, Holt CE. Local translation of extranuclear lamin B promotes axon maintenance. Cell 2012; 148:752 - 64; http://dx.doi.org/10.1016/j.cell.2011.11.064; PMID: 22341447
   PubMed Web of Science ®Google Scholar
• Sepp-Lorenzino L, Rosen N. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. J Biol Chem 1998; 273:20243 - 51; http://dx.doi.org/10.1074/jbc.273.32.20243; PMID: 9685373
   PubMed Web of Science ®Google Scholar
• Wang Y, Ostlund C, Choi JC, Swayne TC, Gundersen GG, Worman HJ. Blocking farnesylation of the prelamin A variant in Hutchinson-Gilford progeria syndrome alters the distribution of A-type lamins. Nucleus 2012; 3:452 - 62; http://dx.doi.org/10.4161/nucl.21675; PMID: 22895092
   PubMed Web of Science ®Google Scholar
• Sinensky M, Fantle K, Dalton M. An antibody which specifically recognizes prelamin A but not mature lamin A: application to detection of blocks in farnesylation-dependent protein processing. Cancer Res 1994; 54:3229 - 32; PMID: 8205544
   PubMed Web of Science ®Google Scholar
• Dreyfuss G, Adam SA, Choi YD. Physical change in cytoplasmic messenger ribonucleoproteins in cells treated with inhibitors of mRNA transcription. Mol Cell Biol 1984; 4:415 - 23; PMID: 6717428
   PubMed Web of Science ®Google Scholar
• Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995; 92:9363 - 7; http://dx.doi.org/10.1073/pnas.92.20.9363; PMID: 7568133
   PubMed Web of Science ®Google Scholar
• Yuan J, Wang X, Zhang Y, Hu X, Deng X, Fei J, et al. shRNA transcribed by RNA Pol II promoter induce RNA interference in mammalian cell. Mol Biol Rep 2006; 33:43 - 9; http://dx.doi.org/10.1007/s11033-005-3965-1; PMID: 16636916
   PubMed Web of Science ®Google Scholar